肺癌 KRASG12C 脑转移的试验、审判和机遇。

Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.

出版信息

Clin Cancer Res. 2022 Aug 2;28(15):3179-3181. doi: 10.1158/1078-0432.CCR-22-1137.

Abstract

The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari et al., p. 3318.

摘要

KRAS 抑制剂对脑转移的作用仍相对未知。最近在临床前模型上的研究和正在进行的 KRYSTAL-1 期 Ib 临床试验的初步数据支持 adagrasib（MRTX849）穿透中枢神经系统并控制 KRASG12C 脑转移的潜力。详见 Sabari 等人的相关文章，第 3318 页。